NASDAQ:AVIR

Atea Pharmaceuticals News Headlines

$19.63
-1.69 (-7.93 %)
(As of 05/10/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.45
▼
$21.82
50-Day Range
$21.08
▼
$78.09
52-Week Range
$19.45
▼
$94.17
Volume776,110 shs
Average Volume505,158 shs
Market Capitalization$1.62 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Atea Pharmaceuticals (NASDAQ AVIR) News Headlines Today

SourceHeadline
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 52-Week Low at $19.63Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 52-Week Low at $19.63
americanbankingnews.com - May 10 at 4:54 PM
Atea Pharmaceuticals (AVIR) Scheduled to Post Earnings on ThursdayAtea Pharmaceuticals (AVIR) Scheduled to Post Earnings on Thursday
americanbankingnews.com - May 7 at 9:15 AM
Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021
finance.yahoo.com - May 6 at 11:17 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month Low at $23.35Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month Low at $23.35
americanbankingnews.com - May 3 at 11:46 AM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short InterestAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short Interest
americanbankingnews.com - May 2 at 6:24 AM
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
finance.yahoo.com - April 29 at 10:18 AM
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With DosingAtea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With Dosing
finance.yahoo.com - April 29 at 10:18 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Sees Large Volume IncreaseAtea Pharmaceuticals (NASDAQ:AVIR) Sees Large Volume Increase
americanbankingnews.com - April 28 at 1:20 PM
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 5.3% Atea Pharmaceuticals (NASDAQ:AVIR) Shares Down 5.3%
americanbankingnews.com - April 27 at 3:46 PM
Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 22 at 10:34 AM
Atea Pharmaceuticals Enters Oversold Territory (AVIR)Atea Pharmaceuticals Enters Oversold Territory (AVIR)
nasdaq.com - April 21 at 5:40 PM
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 7.7%Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Down 7.7%
americanbankingnews.com - April 21 at 11:43 AM
UPDATE 1-Roche looking for new place to test COVID-19 pill after cases plummet in UKUPDATE 1-Roche looking for new place to test COVID-19 pill after cases plummet in UK
finance.yahoo.com - April 21 at 7:39 AM
Atea Pharmaceuticals, Inc.s (NASDAQ:AVIR) Lock-Up Period Will End on April 28thAtea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Lock-Up Period Will End on April 28th
americanbankingnews.com - April 21 at 1:14 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Shares Gap Up to $44.50Atea Pharmaceuticals (NASDAQ:AVIR) Shares Gap Up to $44.50
americanbankingnews.com - April 20 at 11:36 AM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 38.8% in MarchAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Up 38.8% in March
americanbankingnews.com - April 18 at 5:42 AM
Atea Pharmaceuticals (AVIR) Is in Oversold Territory: Whats Next?Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?
finance.yahoo.com - April 16 at 9:00 AM
Industry Analysts Just Made A Dazzling Upgrade To Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue ForecastsIndustry Analysts Just Made A Dazzling Upgrade To Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts
nasdaq.com - April 8 at 7:57 AM
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
finance.yahoo.com - April 8 at 7:57 AM
Atea Pharmaceuticals IncAtea Pharmaceuticals Inc
reuters.com - April 1 at 4:38 AM
Atea Pharmaceuticals Enters Oversold TerritoryAtea Pharmaceuticals Enters Oversold Territory
nasdaq.com - March 30 at 8:46 PM
Atea Pharmaceuticals Inc to Host Earnings CallAtea Pharmaceuticals Inc to Host Earnings Call
finance.yahoo.com - March 30 at 3:45 PM
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021
finance.yahoo.com - March 23 at 7:51 AM
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic InfectionsAtea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
finance.yahoo.com - March 6 at 9:45 AM
AVIR Jul 2021 90.000 putAVIR Jul 2021 90.000 put
ca.finance.yahoo.com - February 19 at 11:11 PM
AVIR Mar 2021 110.000 callAVIR Mar 2021 110.000 call
ca.finance.yahoo.com - February 19 at 6:09 PM
AVIR Feb 2021 80.000 putAVIR Feb 2021 80.000 put
ca.finance.yahoo.com - February 19 at 6:09 PM
Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
finance.yahoo.com - February 8 at 5:17 PM
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient SettingAtea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
finance.yahoo.com - February 4 at 8:17 AM
Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its BusinessAtea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
finance.yahoo.com - January 30 at 7:57 AM
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations andAtea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and
bloomberg.com - January 21 at 6:05 PM
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate CommunicationsAtea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
finance.yahoo.com - January 19 at 5:57 PM
AVIR Crosses Above Average Analyst TargetAVIR Crosses Above Average Analyst Target
nasdaq.com - January 15 at 10:40 PM
RGEN Jan 2021 195.000 putRGEN Jan 2021 195.000 put
sg.finance.yahoo.com - December 27 at 11:28 PM
AVIRAVIR
seekingalpha.com - December 25 at 12:47 AM
Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare ConferenceAtea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 8:06 AM
Atea Pharmaceuticals Added to Russell 2000 IndexAtea Pharmaceuticals Added to Russell 2000 Index
finance.yahoo.com - December 18 at 8:31 AM
Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx ConferenceAtea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 25 at 7:29 AM
This page was last updated on 5/11/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.